HCXY
Hercules Capital, Inc.
NYSE · Financial Services · Asset Management · US
$25.02
+0.08%Aug 19, 2026, 10:01 UTC
Kroll Bond Rating Agency affirmed Hercules Capital's investment grade corporate and credit rating of BBB+ with a stable outlook.
Aug 13, 2026, 20:05 UTC
4D Molecular Therapeutics entered into a strategic credit facility agreement with Hercules Capital for up to $200 million, with an initial draw of $20 million.
Aug 10, 2026, 11:00 UTC
MoonLake Immunotherapeutics announced positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, meeting all clinical endpoints at Week 16, and reported second quarter 2026 financial results with $537.0 million in cash and cash equivalents as of the end of the quarter.
Source:Jul 30, 2026, 20:05 UTC
Hercules Capital reported its financial results for the second quarter ended June 30, 2026.
Jul 28, 2026, 10:00 UTC
Hercules Capital's Board of Directors declared a total cash distribution of $0.47 per share for the second quarter of 2026.
Source:Jul 21, 2026, 20:15 UTC
Hercules Capital priced an underwritten public offering of $325.0 million in 6.300% notes due July 2031.
Jun 30, 2026, 00:00 UTC
Disc Medicine, Inc. amended its secured credit facility with Hercules Capital, Inc. on June 25, 2026, extending drawdown periods, splitting the $50 million Tranche 1-C Advance into two $25 million tranches, and drawing down $30 million of the Tranche 1-B Advance.
Jun 29, 2026, 12:00 UTC
4D Molecular Therapeutics entered into a strategic credit facility agreement with Hercules Capital for up to $200 million.
Source:Jun 17, 2026, 13:45 UTC
A lawsuit was filed against Hercules Capital, Inc. over alleged securities laws violations.
Jun 10, 2026, 13:00 UTC
Beren Therapeutics secured $300 million in combined financing, including $135 million equity and up to $165 million debt facility from Hercules Capital.
Source: